Deliver a professional weight loss service through Scripter's structured consultation pathway. Supply: Oral semaglutide weight-management tablets, titrated dosing.

Book a demo Browse all PGDs

What is Wegovy tablet (oral semaglutide)?

Oral semaglutide brings GLP-1 therapy to a daily tablet, using an absorption enhancer so the peptide survives the stomach. It suits patients who want GLP-1 results without a weekly injection, with the same appetite-reduction mechanism.

The condition it treats

Obesity management with an oral GLP-1 opens the therapy to needle-averse patients, but the dosing rules (empty stomach, small water volume, 30-minute wait) make counselling the difference between effect and expensive disappointment.

How the service runs on Scripter

Patients book online, complete the pre-consultation questionnaire, and the guided pathway walks the practitioner through the weight loss consultation with the screening and counselling steps built in. The supply decision, the record and any GP notification are produced in the same flow, documented against the exact protocol version in force.

Training and eligibility requirements.

Who can deliver this service, and who it can be delivered to. The governing PGD document defines the definitive inclusion, exclusion and supply criteria; the Scripter consultation pathway enforces them, and every consultation is documented against the protocol version it ran under.

Practitioner training

✓Registered healthcare professional from a profession authorised to supply under PGDs (Schedule 16, Part 4 of the Human Medicines Regulations 2012), such as a pharmacist, nurse, paramedic or physiotherapist, with current registration with their professional regulator

✓Practising from premises suitable for the service, such as registered pharmacy premises or a registered clinic

✓Assessed clinical competency for this service, declared and reviewed as part of PGD authorisation

✓Sign-off against the current version of this PGD in Scripter before first supply; sign-offs expire automatically when the protocol is updated, and the platform notifies everyone affected

✓In-date basic life support and safeguarding training

✓Indemnity arrangements covering the service

Patient eligibility

✓Adults meeting the governing PGD's BMI and comorbidity criteria

✓Pregnancy and breastfeeding excluded

✓Thyroid carcinoma and pancreatitis history screened as for injectable GLP-1s

✓Dosing-condition counselling completed: empty stomach, limited water, wait before food

Wegovy tablet (oral semaglutide) PGD questions

Tablet or injection: how do patients choose?+

Effectiveness favours the established injectable at maintenance doses; convenience and needle comfort favour the tablet. The consultation lays out both honestly and records the choice.

Why is the empty-stomach rule such a big deal?+

Food or too much water destroys the tablet's absorption; taken wrong, it simply does not work. The pathway drills the routine because adherence to it is the treatment.

Can a patient switch between tablet and injection?+

Switching is possible within the governing PGDs' criteria; the record carries the dose history that makes the equivalent step obvious.

More weight loss PGDs.

Related protocols in the same category, all delivered through the same platform.

Run a weight loss service without the paperwork.

See the consultation pathway, the sign-off tracking and the record it produces in a free 30-minute demo.

Book a demo Contact us

Built for pharmacists, by pharmacists.